Skip to main
CRBU

Caribou Biosciences (CRBU) Stock Forecast & Price Target

Caribou Biosciences (CRBU) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 75%
Buy 25%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Caribou Biosciences is a promising biopharmaceutical company driven by its transformative and innovative approach to developing therapies for patients with hematologic malignancies. Its strong focus on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates and its successful operations in the United States, where it derives the majority of its revenue, highlight its potential for growth and success. Despite some impairment charges reported in its financials, the company remains financially stable and constantly strives to expand its capabilities and reach, which solidifies its positive outlook for the future.

Bears say

Caribou Biosciences is facing potential risks and challenges due to upcoming catalysts, such as longer follow-up data from the ANTLER trial and initial data for CB-011. These risks, combined with our DCF-based valuation and probability of approval assumptions, lead us to have a skeptical outlook on the stock. Additionally, potential risks such as negative clinical results, delays in advancing candidates, and competitive landscape risks could also negatively impact the company's future success.

Caribou Biosciences (CRBU) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 75% of analysts recommend a Strong Buy, 25% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Caribou Biosciences and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Caribou Biosciences (CRBU) Forecast

Analysts have given Caribou Biosciences (CRBU) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Caribou Biosciences (CRBU) has a Strong Buy consensus rating as of Aug 8, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.25, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.25, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Caribou Biosciences (CRBU)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.